AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator turned it down with a request for more data. Now, Vyalev (foscarbidopa ...

AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...

AbbVie has launched its Produodopa therapy for Parkinson’s disease onto the market in the EU, becoming the first and only 24-hour levodopa-based subcutaneous infusion therapy for the ...

The US Food and Drug Administration (FDA) rejected three prior regulatory applications before granting approval.

AbbVie projects they'll generate sales of over $31 billion ... It recently reported positive late-stage results for the drug ...

AbbVie (NYSE:ABBV) will report Q4 2024 results ... as well as in Alzheimer's disease psychosis and Parkinson's disease psychosis. 2025 guidance - return to "robust" revenue growth despite ...

Alpha-synuclein inhibitors are a class of investigational therapies targeting the pathological aggregation of alpha-synuclein, a protein implicated i ...

This follows the approval of Vyalev, a Parkinson's disease treatment by AbbVie, which received FDA approval in October of last year. Parkinson's disease is a condition that causes muscles to ...

If successful, AbbVie plans to file with the FDA in 2025 for a potential launch in 2026. Other notable pipeline assets include Tavapadon for Parkinson's disease and ABBV-400 for solid tumors.

According to DelveInsight’s epidemiology model, the total diagnosed prevalent cases of Parkinson’s disease were approximately 1,210 thousand in the US in 2023 which is expected to increase during the ...